Why is "Major depressive disorder" trending?

Search Interest Perspective

• Orexin receptor antagonists for major depressive disorder: perspectives from a systematic review and meta-analysis - Nature
• Figure4 | Neurobiological mechanisms in major depressive disorder - CMAJ
• Major Depressive Disorder Shares Immune Abnormalities and Potential Therapeutic Targets With Inflammatory Skin Diseases, According to New Study - Mount Sinai
• Use of ammoxetine is safe and effective in adults with major depressive disorder - 2 Minute Medicine
• Major Depressive Disorder Research Roundup: January 23, 2026 - Psychiatric Times
• How to Spot Major Depressive Disorder Symptoms - HealthCentral
• Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial - Psychiatry Online
• Short-acting psychedelic DMT shows promise as a rapid treatment for major depressive disorder - PsyPost
• Optimized multichannel 4 mA vs conventional transcranial direct current stimulation for major depressive disorder: A randomized sham-controlled trial - Nature
• Figure1 | Neurobiological mechanisms in major depressive disorder - CMAJ
• This Year In Major Depressive Disorder - Psychiatric Times
• A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial - Nature
• Subtypes of adolescent major depressive disorder characterized by divergent information dynamics in sensory-association cortices - Nature
• Energy inefficiency underpinning brain state dysregulation in individuals with major depressive disorder - Nature
• Unraveling spatiotemporal dynamics in transdiagnosis subtypes of major depressive disorder and bipolar disorder: insights from co-activation patterns and treatment response - Nature
• Major depressive disorder shares systemic immune signatures and potential therapeutic targets with inflammatory skin diseases | Molecular Psychiatry - Nature
• Gray and White matter microstructural alterations in major depressive disorder: a multi-center diffusion imaging study - Nature
• Uncovering oscillatory dysregulation associated with suicide risk in major depressive disorder: a narrative review - Nature
• Alterations in aperiodic neural activity associated with major depressive disorder - Nature
• Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder - Nature
• Improving Both Mood and Anxiety: What Cariprazine Brings to the Treatment of Major Depressive Disorder - mghpsychnews.org
• Brain causality alterations in major depressive disorder treatment - Frontiers
• Short-term nitrous oxide treatment could benefit patients with major depressive disorder - News-Medical
• Reduced synapse protein SNAP 25 found in patients with major depressive disorder and schizophrenia - Medical Xpress
• Brain 'fingerprints' are less unique in major depressive disorder, study suggests - Medical Xpress
• Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial - Psychiatrist.com
• Lifestyle Psychiatry for Supporting Individuals With Major Depressive Disorder - Psychiatric Times
• Emoface: AI-assisted diagnostic model for differentiating major depressive disorder and bipolar disorder via facial biomarkers - Nature
• Glutamatergic Pathways in Major Depressive Disorder: Insights From Juan D. Oms, MD, FAPA - Psychiatric Times
• How Does Major Depressive Disorder Affect Other Conditions in Patients? - Psychiatry Advisor
• A working model linking the psychopathology and pathophysiology of major depressive disorder - an umbrella review of neuroimaging studies and a conceptual framework | Molecular Psychiatry - Nature
• The Risk of Obstructive Sleep Apnea Among Patients With Major Depressive Disorder and Generalized Anxiety Disorder in Saudi Arabia: A Cross-Sectional Study - Cureus
• Evaluating a New Addition to the Treatment Toolbox for Major Depressive Disorder - Psychiatry Online
• New ECNP Poster Data on Adjunctive Lumateperone for Major Depressive Disorder - Psychiatric Times
• Phase 2 Proof-Of-Concept Study Evaluating BHV-7000 for Major Depressive Disorder Fails to Meet Primary Endpoint - Psychiatric Times
• Management of Major Depressive Disorder in Adults: Guidelines From CANMAT - American Academy of Family Physicians | AAFP
• Major Depressive Disorder: Biomarkers in Brain and Blood Identified - European Medical Journal
• FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder - Pharmacy Times
• Layered vulnerabilities in young adults with major depressive disorder: personality, coping, and cognition - Frontiers
• EEG microstate analysis between patients with major depressive disorder, subclinical depression, and healthy controls - Frontiers
• Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial - Psychiatrist.com
• Transcutaneous auricular vagus nerve stimulation for major depressive disorder: current evidence and future research directions - Frontiers
• Case Report: rTMS for recurrent major depressive disorder and generalized anxiety disorder comorbid with atrial fibrillation - Frontiers
• Sobel neural network for EEG-based major depressive disorder screening - Frontiers
• Which aspects of anhedonia predict response to pharmacotherapy in major depressive disorder? - Cambridge University Press & Assessment
• Glymphatic dysfunction associated with cortisol dysregulation in major depressive disorder - Nature
• LLMs can identify major depressive disorder via voice note recordings - Medical Xpress
• Brainwaves meet soundwaves: ultrasound stimulation for treating major depressive disorder by targeting the subcallosal cingulate cortex - Nature
• Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder - PR Newswire
• When Rest Doesn’t Help: How to Manage Major Depressive Disorder–Related Fatigue - Everyday Health
• How to Measure Real Recovery in Major Depressive Disorder - Everyday Health
• Immune system abnormalities identified as core mechanism in major depressive disorder - News-Medical
• The Role of Willpower in Major Depressive Disorder: An fMRI Study - Yulug - 2025 - Brain and Behavior - Wiley Online Library
• Optimizing Treatment for Worsening of Major Depressive Disorder - HMP Global Learning Network
• Exploring the capabilities of repetitive transcranial magnetic stimulation in major depressive disorder: Dynamic causal modeling of the neural network | Translational Psychiatry - Nature
• Is cardiac autonomic control affected in major depressive disorder? A systematic review of heart rate variability studies - Nature
• Clinical relevance of brain functional connectome uniqueness in major depressive disorder - Asia Research News |
• Major depressive disorder in multiple sclerosis associated with differences in disease modifying therapy and demographics - Frontiers
• Esketamine in a Patient With Major Depressive Disorder and Polysubstance Use: A Case Report - Cureus
• A “Surprise” Miss: NBI-1070770 for Major Depressive Disorder Fails in Phase 2 Study - Psychiatric Times
• Editorial: Understanding vulnerability to major depressive disorder - Frontiers
• Clinical relevance of brain functional connectome uniqueness in major depressive disorder - EurekAlert!
• FDA Approves Caplyta for Adjunctive Treatment of Major Depressive Disorder - Psychiatric Times
• FDA approves neuromodulation device for adults with major depressive disorder - Healio
• SAFETY DESK: Living with major depressive disorder - WOWT
• Quantifying Sample Representation in Global Pharmacogenomic Studies of Major Depressive Disorder: A Systematic Review - Wiley
• What doctors wish patients knew about seasonal affective disorder - American Medical Association
• FDA Approves Lumateperone as Add-On Therapy for Major Depressive Disorder - The American Journal of Managed Care® (AJMC®)
• Phase 3 Study of Lumateperone as Adjunct to Antidepressant Therapy for Major Depressive Disorder and Anxious Distress Meets End Points - Psychiatric Times
• Detecting schizophrenia, bipolar disorder, psychosis vulnerability and major depressive disorder from 5 minutes of online-collected speech | Translational Psychiatry - Nature
• GeneSight test improves outcomes in major depressive disorder, meta-analysis shows - News-Medical
• Psilocybin May Benefit Patients With Cancer, Major Depressive Disorder - The ASCO Post
• Underuse of Adjunctive Therapy in Major Depressive Disorder - Medscape Reference
• Your Financial Guide to Living With Major Depressive Disorder - Everyday Health
• Exploring the link between leaky blood-brain barrier and major depressive disorder - News-Medical
• Effects of adjunctive brexpiprazole in patients with major depressive disorder and sleep disturbance: a post hoc analysis of three randomized trials - Frontiers
• Leveraging Digital Monitoring for Major Depressive Disorder - The American Journal of Managed Care® (AJMC®)
• Genomics of schizophrenia, bipolar disorder and major depressive disorder - Nature
• FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results - Applied Clinical Trials
• New Positive Phase 2 Data on Osavampator for Major Depressive Disorder - Psychiatric Times
• FDA Clears Accelerated Protocol for Deep TMS to Treat Major Depressive Disorder - Psychiatric Times
• Insights on Seltorexant as Adjunctive Treatment for Major Depressive Disorder: A Conversation With Andrew Cutler, MD - Psychiatric Times
• Novel Therapeutic Targets for Major Depressive Disorder: In Conversation With Ginger Shupe, MD - Psychiatric Times
• New Episodes and Suicidal Risks in Bipolar and Major Depressive Disorder Patients During Versus Before Long-Term Treatment With Lithium - Wiley Online Library
• Differentiating Subtypes of Major Depressive Disorder Using Serum Biomarkers - Psychiatrist.com
• Prognostic and Prescriptive Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report - Psychiatrist.com
• Graphene research, innovation and collaboration - Graphene Flagship
• Structural and functional thalamic alterations in major depressive disorder with comorbid chronic pain - Nature
• Lumateperone (Caplyta) for Major Depressive Disorder (MDD): Expert Insights, Key Facts - WebMD
• Major Depressive Disorder Research Roundup: July 25, 2025 - Psychiatric Times
• What Is Depression With Mixed Features? - Verywell Mind
• Lumateperone linked to greater major depressive disorder symptom improvement vs. placebo - Healio
• Deciphering transcriptomic signatures in schizophrenia, bipolar disorder, and major depressive disorder - Frontiers
• Beyond the label “major depressive disorder”—detailed characterization of study population matters for EEG-biomarker research - Frontiers
• Large-scale transcriptomic analyses of major depressive disorder reveal convergent dysregulation of synaptic pathways in excitatory neurons - Nature
• Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 - PR Newswire
• Metagenomics reveals unique gut mycobiome biomarkers in major depressive disorder - a non-invasive method - Frontiers
• Reduced Parahippocampal Volume Found to Be Related to Major Depressive Disorder in Study Using 7T MRI - Psychiatric Times
• Effects of neuroticism on suicide risk in major depressive disorder and bipolar disorder - Frontiers
• Exploring ketamine as a treatment for people with anorexia and major depressive disorder: the EDEN study - King's College London